Neel Nayan Pharma Pvt Ltd - Due diligence report

A 360° intelligence report on Neel Nayan Pharma Pvt Ltd: trust score, financial health, credit view, compliance, directors, growth and distr…

1989-11-21 Gandevi, Gujarat Active Unlisted Active Compliant
Share
Connect MCP
NN Neel Nayan Pharma Pvt Ltd
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Neel Nayan Pharma Pvt Ltd — 360° Intelligence Report

Generated from MCA filings & public records
81/100
Trust Score
Low Risk

Neel Nayan Pharma Pvt Ltd is assessed as Low Risk with a Trust Score of 81/100. Neel Nayan Pharma Pvt Ltd is an active private limited indian non-government company incorporated in 1989, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 10 Aug 2026 from the latest processed filings. Neel Nayan Pharma Pvt Ltd snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
73/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
30/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 30/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 4 open (10.58 cr) · 3 satisfied (51.31 Lakh).

Banking relationships (from registered charges)
LenderChargesAmount
Sidbi1 48.0 cr
State Bank Of India1 48.0 cr
Others1 48.0 cr
Bank Of Baroda3 48.0 cr
Axis Bank Limited1 48.0 cr
Compliance Score: 73/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (77 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
VIRDEEPSINH LAKHDHIRSINH SARVAIYA 01234567 Director 01/04/2018 6 yrs Approved
MONICA PANT 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 9 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 36+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
4 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 20.30 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment53/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 10.58 cr already registered.
  • Compliance record supports lending.
Investor view83/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
31 Jan 2025
Charge created
State Bank Of India - 4.80 cr
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
28 Mar 2024
Charge created
Others - 68.00 Lakh
23 Jun 2023
Charge created
Sidbi - 5.00 cr
30 Sep 2022
Director ceased
VIRDEEPSINH LAKHDHIRSINH SARVAIYA
Director ceased
MONICA PANT
31 Mar 2020
Share transfer (FY 2020)
62000.00000000 shares to VEMULA THANMAYEE
Share transfer (FY 2020)
30000.00000000 shares to VEMULA THANMAYEE
Share transfer (FY 2020)
6000.00000000 shares to PANT MONICA
Share transfer (FY 2020)
7000.00000000 shares to SARVAIYA VIRDEEPSINH
Share transfer (FY 2020)
23000.00000000 shares to SARVAIYA VIRDEEPSINH
Share transfer (FY 2020)
30000.00000000 shares to SARVAIYA VIRDEEPSINH
Share transfer (FY 2020)
1500.00000000 shares to PANT MONICA
11 Oct 2019
Director ceased
BRIJKUMAR KANTILAL SHAH
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ddreg U24232HR2012PTC047936 Gurgaon, Haryana, India
Zumutor U73200KA2015FTC081944 Bangalore, Karnataka, India
Pharmascroll Research And Consulting Private Limited U93000TG2017PTC117856 Shaikpet, Telangana, India
Nasmed Diagnostic Private Limited U33209GJ2022PTC129341 Nandoli, Gujarat, India
Qbit Labs U29309DL2020PTC363015 Delhi, Delhi, India
Teadus Pharma Private Limited U24230TG2023PTC170281 Hyderabad, Telangana, India
Verdant U32201KL2007PTC021214 Kochi, Kerala, India
Cod Research U73100GJ2019PTC110308 Ahmadabad City, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Neel Nayan Pharma Pvt Ltd before audits and certifications: compliance score 73/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Neel Nayan Pharma Pvt Ltd: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Neel Nayan Pharma Pvt Ltd - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Neel Nayan Pharma Pvt Ltd pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Neel Nayan Pharma Pvt Ltd - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Neel Nayan Pharma Pvt Ltd an active company?

Neel Nayan Pharma Pvt Ltd has MCA status “Active” with a compliance score of 73/100 (Moderate).

Is Neel Nayan Pharma Pvt Ltd financially healthy?

Neel Nayan Pharma Pvt Ltd has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Neel Nayan Pharma Pvt Ltd?

Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Neel Nayan Pharma Pvt Ltd?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Neel Nayan Pharma Pvt Ltd have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Neel Nayan Pharma Pvt Ltd up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 73/100 (Moderate).

Is it risky to lend to Neel Nayan Pharma Pvt Ltd?

Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.